Combining structure and function to evaluate glaucomatous progression: implications for the design of clinical trials

► An index combining structural and functional glaucoma assessment has been developed. ► The combined index estimates retinal ganglion cell damage. ► The index performed well for diagnosing and detecting disease progression. ► The combined approach may be useful as an outcome measure in clinical trials.